TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00671723

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline:
Description: Nebulized isotonic saline solution (4 ml of 0.9 % NaCl) twice daily, for a fixed period of 15 min, after a 15 min premedication with nebulized albuterol (2.5 mg diluted in 3 ml of 0.9 % NaCl).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hypertonic Saline
Description: Nebulized hypertonic saline solution (4 ml of 7 % NaCl) twice daily, for a fixed period of 15 min, after a 15 min premedication with nebulized albuterol (2.5 mg diluted in 3 ml of 0.9 % NaCl).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dornase alpha
Description: 2.5 mg of DNase (Dornase alpha, PULMOZYME® , Genentech, South San Francisco, CA), nebulized twice daily, after a 15 min premedication with nebulized albuterol (2.5 mg diluted in 3 ml of 0.9 % NaCl).
Study: NCT02574858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QRH-882260
Description: The investigational agent to be used in this study is a fluorescently-labeled peptide composed of a 7-amino acid sequence attached to Cy5.
Study: NCT04051476

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3-g footbath
Description: A ten-minute pre-intervention rest period followed by a 20-minute footbath with 12 l of warm water (40 °C) and 36 g ginger flour (3 g per l), followed by a ten-minute post-intervention rest period.
Study: NCT02452996

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GNbAC1
Description: Single dose of IMP, IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GNbAC1
Description: Single dose of IMP, IV infusion
Study: NCT02138019

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fibrin Glue assisted external eye surgery

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fibrin glue
Study: NCT04051476

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 6-g footbath
Description: A ten-minute pre-intervention rest period followed by a 20-minute footbath with 12 l of warm water (40 °C) and 72 g ginger flour (6 g per l), followed by a ten-minute post-intervention rest period.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 12-g footbath
Description: A ten-minute pre-intervention rest period followed by a 20-minute footbath with 12 l of warm water (40 °C) and 144 g ginger flour (12 g per l), followed by a ten-minute post-intervention rest period.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Warm water footbath
Description: A ten-minute pre-intervention rest period followed by a 20-minute footbath with 12 l of warm water (40 °C), followed by a ten-minute post-intervention rest period.
Study: NCT03071003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SENS-401
Description: Oral Administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SENS-401
Description: Oral Administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SENS-401
Description: Oral Administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral Administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral Administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral Administration
Study: NCT04632407

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Flax milk
Description: See above

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oat fibre milk
Description: See above
Study: NCT00920036

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: StressEraser
Description: A hand-held biofeedback device that facilitates resonant frequency of respiration
Study: NCT03411707

Intervention type: DIAGNOSTIC_TEST
Intervention: Stool DNA test
Description: Stool DNA test could detect specific gene methylation in stool DNA. Blood mRNA test could detect specific set of gene expression in blood.
Study: NCT02058758

Intervention type: DEVICE
Intervention: Magnetic Resonance Imaging
Description: MRI scanning with novel acquisition, reconstruction, and/or analysis methods.

Intervention type: DEVICE
Intervention: Magnetic Resonance Imaging
Description: MRI scanning with novel acquisition, reconstruction, and/or analysis methods.
Study: NCT00599261

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ICD/pacemaker pocket revision
Description: Pocket revision consists of complete removal of the fibrous capsule surrounding the device and leads

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ICD/pacemaker pocket revision
Description: Pocket revision consists of complete removal of the fibrous capsule surrounding the device and leads
Study: NCT02394730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorapaxar
Description: 2.5mg of vorapaxar taken orally once daily for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar pill taken orally once daily for 12 weeks
Study: NCT01205958

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: acupuncture
Description: Over an three-week period, one group(n=15) gets western medicine treatment(drug medication); another group(n=15) gets oriental medicine treatment(individualized needling 2-3 times a week); the other group(n=15) gets western medicine plus oriental medicine treatment for 3 weeks

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: acupuncture
Description: Over an three-week period, one group(n=15) gets western medicine treatment(drug medication); another group(n=15) gets oriental medicine treatment(individualized needling 2-3 times a week); the other group(n=15) gets western medicine plus oriental medicine treatment for 3 weeks

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: acupuncture
Description: Over an three-week period, one group(n=15) gets western medicine treatment(drug medication); another group(n=15) gets oriental medicine treatment(individualized needling 2-3 times a week); the other group(n=15) gets western medicine plus oriental medicine treatment for 3 weeks
Study: NCT01582971

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reflexology
Description: Friend/family member trained in foot reflexology protocol by certified reflexologist; friend/family member provides 4 weekly sessions to patient
Study: NCT04494464

Intervention type: OTHER
Intervention: No intervention
Study: NCT02902029

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: 960 mg vemurafenib BID until progression or unacceptable toxicity develops

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: 960 mg vemurafenib BID until progression or unacceptable toxicity develops

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: 60 mg cobimetinib QD, 21/7 until progression or unacceptable toxicity develops

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: 60 mg cobimetinib QD, 21/7 until progression or unacceptable toxicity develops

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: 1200 mg atezolizumab administered intravenously on day 1 of each 21 day-cycle. Will be given until progression or unacceptable toxicity develops

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: 1200 mg atezolizumab administered intravenously on day 1 of each 21 day-cycle. Will be given until progression or unacceptable toxicity develops
Study: NCT01155596

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: negative pressure ventilator use
Description: Body ventilators that assist ventilation by applying intermittent subatmospheric pressure around the thorax, abdomen, or airway and periodically expand the chest wall and inflate the lungs. They are relatively simple to operate and do not require tracheostomy. Chest cuirass is used in this study.
Study: NCT04631068

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Cataract surgery
Description: Small incision cataract surgery with implantation of an intraocular lens

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cataract surgery
Description: Small incision cataract surgery with implantation of an intraocular lens
Study: NCT02333591

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GlucagonLikePeptide-1 (7-36)
Description: Diluted in saline and human serum albumin, then infused intravenously for 2,5 hours.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GlucagonLikePeptide-1 (9-36)
Description: Diluted in saline and human serum albumin, then infused intravenously for 2,5 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: Infused intravenously for 2,5 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: Infused intravenously for 2,5 hours.
Study: NCT02943005

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rotator cuff repair

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rotator cuff repair
Study: NCT02085057

Intervention type: PROCEDURE
Intervention: Functional Magnetic Resonance Imaging

Intervention type: PROCEDURE
Intervention: Functional Magnetic Resonance Imaging

Intervention type: PROCEDURE
Intervention: Functional Magnetic Resonance Imaging

Intervention type: PROCEDURE
Intervention: Functional Magnetic Resonance Imaging
Study: NCT03120637

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylene Blue
Study: NCT00797485

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: bevacizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Given orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluorouracil
Description: Given IV
Study: NCT03850613

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: E-painting mobile app
Description: The subjects can use the newly developed mobile app to draw their own pictures at the time convenient to them.
Study: NCT02742519

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ivacaftor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ivacaftor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ivacaftor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT00886756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8529
Description: Oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral
Study: NCT03407846

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hystrectomy
Description: Total laparscopic hystrectomy versus total abdominal hystrectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hystrectomy
Description: Total laparscopic hystrectomy versus total abdominal hystrectomy
Study: NCT00132964

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Below knee walking cast
Description: Not required

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Removable ankle brace
Description: not required
Study: NCT04011631

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Internal defibrillation during cardiac surgery, using the iD-system
Description: When ventricular fibrillation of ventricular tachycardia occurs during surgery, the iD-Paddle will be applied directly to the heart. A maximum of 4 shocks are delivered to the heart to restore normal sinus rhythm. If 4 shocks are not successful standard operating procedure will be enable conform hospital protocol.
Study: NCT00088413

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PANVAC-V
Description: Patients receive 2 x 10(8) pfu PANVAC-V (vaccinia) subcutaneously on Day 1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PANVAC-F
Description: Patients receive 1 x 10(9) pfu PANVAC-F (fowlpox) or about days 15, 29, and 43 then every month for 12 doses then every 3 months until disease progression or toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sargramostim (GM-CSF, Leukine)
Description: 100g sargramostim will be given subcutaneously at the site of the vaccination on each vaccination day and for three consecutive days thereafter.
Study: NCT00584246

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin (Lyrica)
Description: 50 - 150 mg po qhs for 2 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pregabalin (Lyrica)
Description: 50 - 150 mg po qhs for 2 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 50 - 150 mg po qhs for 2 months
Study: NCT02265432

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: General physical activity educational materials

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: General physical activity educational materials

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wearable activity tracking devices (fitbit)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: online map

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalized text messages
Study: NCT01203813

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Decision Support
Description: Physicians randomized to the intervention will receive:~1. Electronic alerts during office visits for patients with chronic kidney disease~2. Opportunity to enroll their patients with chronic kidney disease in a self management support outreach program
Study: NCT01424670

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delamanid + OBR
Description: The assigned doses of delamanid were administered with an OBR. The selection and administration of the OBR were based on WHO's guidelines for the programmatic management of drug-resistant TB, in conjunction with national TB program guidelines in each country.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + OBR
Description: Matching placebo was administered with an OBR. The selection and administration of the OBR were based on WHO's guidelines for the programmatic management of drug-resistant TB, in conjunction with national TB program guidelines in each country.
Study: NCT03638427

Intervention type: DIAGNOSTIC_TEST
Intervention: Menstrual Blood Analysis (Menstrual Blood Analysis)
Description: We will be testing women's menstrual blood to investigate the feasibility and efficacy of assessing HR-HPV DNA and HPV E6/E7 mRNA via self-collected menstrual blood from a menstrual pad.
Study: NCT02184559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: comparaison of two methods of administration for analgesia using the same drugs in the same indication after Caesarean section

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: The infiltration continues catheter
Study: NCT04642859

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized Cognitive abilities training battery for reading (CATB-R)
Description: Specially designed Arabic computerized training program for dyslexia
Study: NCT02553902

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sleep position trainer

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mandibular advancement device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous positive airway pressure
Study: NCT01646047

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: multi-component nutritional supplement capsules
Description: two capsules containing nutritional supplements per day for 6 months (vitamin C, mixed tocopherols/tocotrienols, vitamin D, fish oil, lutein, zeaxanthin, pine bark extract, benfotiamine, green tea extract, curcumin)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: multi-component nutritional supplement capsules
Description: two capsules containing nutritional supplements per day for 6 months (vitamin C, mixed tocopherols/tocotrienols, vitamin D, fish oil, lutein, zeaxanthin, pine bark extract, benfotiamine, green tea extract, curcumin)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: multi-component dietary supplement
Description: placebo capsules

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: multi-component dietary supplement
Description: placebo capsules
Study: NCT00842478

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Toothbrushing
Study: NCT05752682

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostic pathway
Description: Each included patient will undergo to the faint and fall protocol, to assess the effectiveness of a patients' flow pathways developed in accordance with the most recent guidelines on syncope of the European Society of cardiology and of guidelines on falls of the American and British Geriatrics Societies.
Study: NCT00797485

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: irinotecan hydrochloride
Description: Given IV
Study: NCT01553058

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab (Humira)
Description: Humira will be given at an initial dose of 80mg followed by 40 mg the second week, subsequent doses will be given at 40mg and follow FDA dosing schedule.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Injection
Description: Placebo injection will be given according to the same dose and schedule as the active comparator.
Study: NCT00797485

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: leucovorin calcium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV
Study: NCT04419324

Intervention type: DEVICE
Group type: OTHER
Intervention: transoral flexible endoscope with magnifying narrow band imaging
Description: To use an esophago-gastroscopy endoscope (OGD) with Narrow Band Imaging (NBI) passed transorally and retroflexed into the nasopharynx to view the nasopharynx with increased magnification and clarity for the diagnosis of nasopharyngeal carcinoma.
Study: NCT03630978

Intervention type: PROCEDURE
Intervention: Liver resection
Description: Major or minor, open or laparoscopic liver resection
Study: NCT01553058

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NB-UVB phototherapy
Description: Phototherapy will be given 3 times per week according to the Fitzpatrick scale for skin types.
Study: NCT03101371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Catheter insertion with Povidone Iodine
Description: The catheter will be treated with Povidone Iodine prior to insertion.
Study: NCT02305654

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ILND - Inguinal Lymph Node Dissection
Description: Surgery to remove the lymph nodes in the groin near to where the cancer first appeared.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Dose 175mg/m2 as part of TIP regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Dose 900mg/m2 as part of TIP regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Dose 15mg/m2 as part of TIP regimen (neoadjuvant chemotherapy arm) Dose 40mg/m2 for use concurrently with raditotherapy (chemoradiotherapy arm)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Dose 15mg/m2 as part of TIP regimen (neoadjuvant chemotherapy arm) Dose 40mg/m2 for use concurrently with raditotherapy (chemoradiotherapy arm)
Study: NCT03101371

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care catheter insertion
Description: Catheter inserted right out of package.
Study: NCT02305654

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity modulated radiation treatment (IMRT)
Description: Treatment with very high energy X-rays (radiotherapy).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prophylactic PLND - pelvic lymph node dissection
Description: Surgery to remove the lymph nodes deeper in the pelvis, further away from where the cancer first appeared, that are at high risk of harbouring cancer.
Study: NCT02160951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LGH447
Description: LGH447, QD
Study: NCT01494922

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EXC 001 (currently called PF-06473871)
Description: Single dose administered by injection at four different times
Study: NCT00972439

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Contraceptive: Ortho-Novum® 1/35

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Contraceptive: Ovcon Fe®
Study: NCT03608787

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: S-STOP
Description: Pseudo-intoxicated patrons will enter each participating establishment and attempt to be served an alcoholic beverage. In the intervention phases, feedback on staff performance will be provided to owners/managers along with supporting materials and a link to a website with a video of a typical pseudo-intoxicated patron. Staff will be provided with a link to a website providing tips for preventing overservice.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: S-STOP
Description: Pseudo-intoxicated patrons will enter each participating establishment and attempt to be served an alcoholic beverage. In the intervention phases, feedback on staff performance will be provided to owners/managers along with supporting materials and a link to a website with a video of a typical pseudo-intoxicated patron. Staff will be provided with a link to a website providing tips for preventing overservice.
Study: NCT01339130

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Computerized tests and Electrophysiological measurements
Description: * Computerized tests: used to evaluate the empathy The participant observes a computer screen on which appears different types of images or words that can evoke an emotion. The participant responds by pressing the screen with his finger. This is a choice between several answers and respond as quickly as possible.~* Electrophysiological measurements: provide a measure of autonomic response to emotional stimuli: galvanic response (GSR) and electromyographic activity (EMG) of facial muscles (corrugator supercilii and zygomatic major).~* Neuropsychological assessment includes an assessment of intellectual efficiency, perceptual and visual-constructive abilities, memory, executive and an assessment of behavior and mood from questionnaires.
Study: NCT02831842

Intervention type: DRUG
Intervention: Anti-EGFR-Containing Regimen
Description: Study protocol does not specify any particular chemotherapy regimen. The data will be collected retrospectively.

Intervention type: DRUG
Intervention: Bevacizumab-containing regimen
Description: Study protocol does not specify any particular bevacizumab containing regimen. The data will be collected retrospectively.

Intervention type: DRUG
Intervention: Chemotherapy
Description: Study protocol does not specify any particular chemotherapy regimen. The data will be collected retrospectively.